Slide 1: Cover letter to stock exchanges
061h February, 2019 (1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Sandra Kurla Complex, Sandra (East), Mumbai- 400 051 Scrip Code: 500087 Scrip Code
Slide 2: Investor Presentation Q3FY19
Investor Presentation Q3FY19 06-02-2019
Slide 3: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 4: Key highlights for the quarter
Key highlights for the quarter India South Africa Continued growth 6% 12% 9.1% 4x 1 across branded markets (Adjusted for re-stocking As per IQVIA Q3’18 As per IQVIA MAT Vs market growth impact in the base of Dec’18 Q3FY18) consecutive quarter of 2 Strong sequential 18% 10% 2nd sequential and YoY gro
Slide 5: Accelerated investments towards a sustainable Specialty business
We have accelerated our investments towards building a sustainable Specialty business Central Nervous System (CNS) Specialty Institutional Specialty Business CPN-101 Tizanidine Patch IV Tramadol Indication: Treatment of Spasticity One PK study (Phase 1a) completed and Cipla’s first large specialty t
Slide 6: Financial Performance – Q3FY19
Financial Performance – Q3FY19 Revenues INR 4,008 Cr EBITDA ~18% to sales Q3 FY19 (Consolidated) Revenue1 Break-up Actuals Global API, Others, vs Q3 FY 18 (Rs Cr) 2% Europe, 5% 4% Total Revenue from 4,008 2% Operations Emerging a) Domestic Sales 1,604 -2% Mkts, 10% India, 40% b) Int’l Sales 2,303 5%
Slide 7: Q3 EBITDA Build-up
Q3 EBITDA Build-up INR Cr Q3FY19 Q3FY18 Q2FY19 Profit Before Tax 449 340 509 Add: - - - Finance Costs 44 9 44 Depreciation, Impairment and Amortisation Expense 293 522 282 Less: - - - Finance and investment related income 66 53 82 EBITDA 720 819 753 Financial numbers are rounded off Investor Present
Slide 8: Financial Performance – 9mFY19
Financial Performance – 9mFY19 Revenues INR 11,958 Cr EBITDA 18.4% to sales 9m FY19 (Consolidated) Revenue1 Break-up Actuals Global API, Others, vs 9m FY 18 (Rs Cr) 2% Europe, 4% 4% Total Revenue from 11,958 4% Operations Emerging a) Domestic Sales 4,829 4% Mkts, 11% India, 40% b) Int’l Sales 6,871
Slide 9: India (Rx + Gx) Sales: Continued momentum across key therapeutic areas
India (Rx + Gx) Sales: Continued momentum across key therapeutic areas; Chronic segment driving growth Q3 Y-o-Y 9m Y-o-Y Rs Cr Rs Cr 6000 1800 1598 1585 4772 1600 5000 6% Double digit Higher base in 4513 1400 growth targeted Q3FY18 due to re- 4000 1200 for Q4 stocking post GST 1000 3000 800 600 2000
Slide 10: North America: Ramp-up across key DTM launches drives continued quarterly growth
North America: Ramp-up across key DTM launches drives continued quarterly growth; post R&D EBITDA positive Q3 Y-o-Y $ Mn Business mix changes over years; Cipla DTM driving strong growth 118 100 18% $mn Cipla B2B Cipla DTM Invagen 287 Esomeprazole Invagen Acquisition 221 223 Pricing pressure on acqui
Slide 11: ANDA Portfolio & Pipeline (As on 31st Dec 2018)
ANDA1 Portfolio & Pipeline (As on 31st Dec 2018) Total 165 26 68 259 ANDAs ANDA Portfolio 180 160 37 140 120 100 53 80 9 4 60 22 40 2 66 3 20 3 40 11 0 9 Approved ANDAs Tentatively Approved ANDAs Under Approval ANDAs 1 Does not include Vet product ANDAs Cipla Ltd PEPFAR 2 Invagen Partnered ANDAs 2 P
Slide 12: SAGA: South Africa, Sub-Saharan Africa and Cipla Global Access
SAGA*: South Africa, Sub-Saharan Africa and Cipla Global Access Q3 Y-o-Y 9m Y-o-Y $ Mn $ Mn SA Private Market SA Private Market ZAR growth ZAR growth 1% 158 11% 104 (ex Animal Health) 54 (ex Animal Health) 30 Impacted by rebasing of South Africa 90 87 Tender business Private 32 31 South Africa Inc A
Slide 13: EM, Europe and API
EM, Europe and API Emerging Markets Europe API $ Mn $ Mn $ Mn 70 30 25 26 26 23 21 60 57 55 -7% -5% 25 20 50 20 40 15 30 15 10 20 10 10 5 5 0 0 0 Q3 FY18 Q3 FY19 Q3 FY18 Q3 FY19 Q3 FY18 Q3 FY19 Biosimilars franchise in the EM: Bevacizumab and Trastuzumab deals Continued momentum in seedings Bu
Slide 14: Strong momentum across our markets with continued focus on operational priorities
Strong momentum across our markets with continued focus on operational priorities; Specialty investments to continue Focused on driving strong growth across our branded markets in India, South Africa and key 1. emerging market territories US Business growth continues to remain strong driven by ramp-
Slide 15: Thank you
Thank you Registered Office : Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013 For any queries, please contact Naveen Bansal Investor.Relations@cipla.com For more information please visit www.cipla.com Investor Presentation: Q3FY19 14